Tag Archives: Attrition Analysis

Government Commitment to the Global Action Against Dementia (WDC / Department of Health)

Posted on November 25, 2015 by Dementia and Elderly Care News

Summary The Department of Health has responded to Raj Long’s Finding a path for a cure for dementia: an independent report into an integrated approach to dementia drug development report, with a Strategy Report and an open letter. There is … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest, World Health Organization (WHO) | Tagged $100m Dementia Discovery Fund, Academia-Industry Partnerships, Academic Research, Accelerated Access Review, AIFA: Italian Medicines Agency, Alzheimer's Association, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, Bill and Melinda Gates Foundation, Biopharmaceutical Companies, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP), Composite End Points, Continuity Plans (WDC and GAAD Agenda), Council for International Organizations of Medical Sciences (CIOMS), Cross-Sector Partnerships, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Integrated Development Initiative, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Department of Health Dementia Challenge, Department of Health’s Integrated Development Initiative, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, EMA: European Medicines Agency, EU Joint Programme on Neurodegenerative Disease Research (JPND), EU’s Neurodegenerative Disease Research Joint Programme (JPND), European Medicines Agency, European Medicines Agency (EMA), European Prevention of Alzheimer's Dementia Consortium (EPAD), First Global Ministerial Conference on Global Action Against Dementia, Foundation Plan Alzheimer’s, GAAD: Global Action Against Dementia, George Freeman MP: Former Life Sciences Minister, Gill Ayling: Deputy Director of Global Action Against Dementia (Department of Health), Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Alzheimer’s Leadership Series (GoALS), Global Alzheimer’s Platform, Global CEO initiative (CEOi) on Alzheimer’s Disease, Global Leadership, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Observatory on Dementia (WHO), Global Outlook, Global Social Investment for Dementia, Government Research Funding, Integrated Development Advisory Group, International Coalition of Medicines Regulatory Agencies, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Pharmaceutical Regulatory Forum, International Programmes, Italian Medicines Agency, Jane Ellison MP: Parliamentary Under Secretary for Public Health, Joint Programme on Neurodegenerative Disease Research (JPND), JPND: Joint Programme on Neurodegenerative Disease Research, Medical Research Council (MRC), Modelling and Extrapolation, Multilateral Cooperation, National Institute for Health Research (NIHR), National Institute of Ageing (NIA), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, NeuroMap, New York Academy of Sciences (NYAS), Observatory on Dementia (WHO), OLS Accelerated Access Review, Organisation for Economic Co-operation and Development (OECD), Partnership and Collaboration, Partnership Working, Philanthropic Funding, Pipeline Databases, Prime Minister’s Challenge On Dementia 2020, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Regulatory Agencies, Regulatory Experts, Research and Development, Research and Innovation, Research Commitment, Research Funding, Resource and Incentives, Risk Benefit Balance, Swiss Medic, University of Newcastle, US National Institute on Aging, WDC: World Dementia Council, WHO Observatory on Dementia, WHO's Global Observatory on Dementia, World Dementia Council, World Health Organisation (WHO) | Leave a comment

Dementia: the R&D Landscape: Mapping UK Dementia Research and Workforce Capacity (RAND Europe / WDC / OHE)

Posted on October 27, 2015 by Dementia and Elderly Care News

Summary The Alzheimer’s Society commissioned RAND Europe to analyse the UK’s dementia research “landscape” and workforce capacity. The following report relates to the state of funding and capacity in dementia research. It covers: An audit of the types of research … Continue reading →

Challenges in Developing Disease-Modifying Treatments for Dementia (Department of Health)

Posted on July 23, 2015 by Dementia and Elderly Care News

Summary Raj Long, the Senior Regulatory Officer at the Bill & Melinda Gates Foundation, explores the problems in developing treatments for dementia. The independent “Finding a Path for the Cure for Dementia” report is a contribution to the G8 Dementia … Continue reading →

Posted in Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged Academia-Industry Partnerships, Academic Research, AIFA: Italian Medicines Agency, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, BfArM: Federal Institute of Drugs and Medical Devices (Germany), Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Burden of Dementia, Canada, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Composite End Points, Consistent Global Development Pathways, Cross-Sector Partnerships, CTEG: Clinical and Technical Expert Group, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Denmark, Department of Health Dementia Challenge, Diagnosis and Referral, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, EMA: European Medicines Agency, European Medicines Agency, European Union, FIH: First in Humans, Financial Incentives, First Global Ministerial Conference on Global Action Against Dementia, Food and Drug Administration, G20 Countries, G7 Countries, G8 Dementia Summit: Global Action Against Dementia, G8 Summit, Gaps in the Basic Science, Germany, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, Government Research Funding, Health Canada, IAP Steering Committee, IDAP Steering Committee, IDAP: International Dementia Advisory Platform, IFPMA: International Federation of Pharmaceutical Manufacturers & Associations, Incentives and Investment, Incentives for Drug Development, Independent Safety Review Committee, Integrated Development Pathway, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Programmes, Italian Medicines Agency, Italy, Japan, Japan: Pharmaceuticals and Medical Devices (Japan), Knowledge Translation, MEB: Medicines Evaluations Board, Medicines and Healthcare Products Regulatory Agency, Medicines Evaluation Board Netherlands, MHRA: Medicines and Healthcare Products Regulatory Agency, Modelling and Extrapolation, Multilateral Cooperation, Multilateral Regulator Cooperation, Netherlands, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, OHE: Office of Health Economics, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Science, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Organisation for Economic Cooperation and Development, Partnership, Partnership and Collaboration, Partnership Working, Patient Viewpoint, Philanthropic Funding, Pipeline Databases, PMDA: Pharmaceutical and Medicines Devices Agency, Public-Private Partnership (PPP), Quantifiable Reproducible Outcome Measures, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Reasons for Termination of Trials, Regulator Perspectives, Regulatory Agencies, Regulatory Experts, Research and Developers’ Status Quo, Research and Development, Research and Innovation, Research Commitment, Research Funding, Research Status Quo, Resource and Incentives, Risk Benefit Balance, Standardisation and Validation of Cognitive Endpoints, Swiss Medic, Switzerland, United States, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO) | Leave a comment

International Meeting of Regulators on Challenges of Dementia Research and Drug Development (MHRA / Department of Health)

Posted on May 26, 2015 by Dementia and Elderly Care News

Summary The Medicines and Healthcare Products Regulatory Agency (MHRA) took part in an international workshop with other regulators, and has released a statement of intent about how to support the development of drugs for dementia. This work is in support … Continue reading →

Posted in Department of Health, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, World Health Organization (WHO) | Tagged Accelerating Alzheimer's Research and Drug Development, Attrition Analysis, Bill and Melinda Gates Foundation, Clinical Trial Efficiency, Composite End Points: Development of Standardised and Validated Endpoint Components, Coordinated Regulatory Action, Danish Health and Medicines Authority, Dementia Research, Department of Health’s Integrated Development Initiative, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Regulation, Drug-Development Pipeline, European Medicines Agency, Expediting Regulatory Approval Procedures: Balancing Benefits and Risks, Federal Institute for Drugs and Medical Devices, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G7 Global Dementia Summit, G8 Dementia Summit, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Leadership, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Global Regulatory Efficiency and Consistency, Health Canada, Incentives, Incentives for Drug Development, International Federation of Pharmaceutical Manufacturers and Associations, Italian Medicines Agency, Market Failure (Dementia Research and Drug Development), Medicines and Healthcare Products Regulatory Agency, Medicines and Healthcare Products Regulatory Agency (MHRA), Medicines Evaluation Board, Multilateral Cooperation: Reducing Unnecessary Testing Replication and Methodology Testing, Office for Life Sciences, Pharmaceutical and Medicines Devices Agency (Japan), Pharmaceutical Regulators, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Regulation, Regulators, Regulatory Barriers, Regulatory Research Dementia Workshop, Regulatory System, Removing Regulatory Barriers, Research and Innovation, Resource and Incentives, Swissmedic, Translational Research, US Food and Drug Administration, WDC: World Dementia Council, WHO: World Health Organization, World Dementia Council | Leave a comment

Tag Archives: Attrition Analysis

International Meeting of Regulators on Challenges of Dementia Research and Drug Development (MHRA / Department of Health)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites